{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:22:54Z","timestamp":1781360574195,"version":"3.54.1"},"reference-count":38,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,1,15]]},"DOI":"10.2169\/internalmedicine.5422-20","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T22:16:57Z","timestamp":1610662617000},"page":"201-208","source":"Crossref","is-referenced-by-count":13,"title":["Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy"],"prefix":"10.2169","volume":"60","author":[{"given":"Tetsuro","family":"Yokokawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"},{"name":"Department of Pulmonary Hypertension, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiomi","family":"Yoshihisa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"},{"name":"Department of Advanced Cardiac Therapeutics, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Misaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"},{"name":"Department of Advanced Cardiac Therapeutics, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kaneshiro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Yamaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kunii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Duchen MR. Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. J Physiol 516: 1-17, 1999."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smyrnias I, Gray SP, Okonko DO, et al. Cardioprotective effect of the mitochondrial unfolded protein response during chronic pressure overload. J Am Coll Cardiol 73: 1795-1806, 2019.","DOI":"10.1016\/j.jacc.2018.12.087"},{"key":"3","unstructured":"3. Shen M, Zhang F, Zhang X. Primary biliary cirrhosis complicated with interstitial lung disease: a prospective study in 178 patients. J Clin Gastroenterol 43: 676-679, 2009."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 135: 1767-1777, 2012.","DOI":"10.1093\/brain\/aws106"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yamaguchi S, Maruyama T, Wakino S, et al. A case of severe osteomalacia caused by Tubulointerstitial nephritis with Fanconi syndrome in asymptomotic primary biliary cirrhosis. BMC Nephrol 16: 187, 2015.","DOI":"10.1186\/s12882-015-0184-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Frostell A, Mendel-Hartvig I, Nelson BD, et al. Mitochondrial autoantigens in primary biliary cirrhosis. Association of disease-specific determinants with a subunit of complex I (NADH-ubiquinone reductase) of the inner mitochondrial membrane. Scand J Immunol 28: 645-652, 1988.","DOI":"10.1111\/j.1365-3083.1988.tb01497.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chalifoux SL, Konyn PG, Choi G, Saab S. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver 11: 771-780, 2017.","DOI":"10.5009\/gnl16365"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Liu B, Zhang FC, Zhang ZL, Zhang W, Gao LX. Interstitial lung disease and Sj\u00f6gren's syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol 27: 1299-1306, 2008.","DOI":"10.1007\/s10067-008-0917-x"},{"key":"9","unstructured":"9. Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L. Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47: 552-556, 2018."},{"key":"10","unstructured":"10. Shen M, Zhang F, Zhang X. Pulmonary hypertension in primary biliary cirrhosis: a prospective study in 178 patients. Scand J Gastroenterol 44: 219-223, 2009."},{"key":"11","unstructured":"11. Saito T, Kodani E, Katayama H, Kusama Y. Eosinophilic myocarditis associated with anti-mitochondrial M2 antibodies: a mechanism underlying the onset of myocarditis. Eur Heart J 39: 3480-3481, 2018."},{"key":"12","unstructured":"12. Bian S, Chen H, Wang L, et al. Cardiac involvement in patients with primary biliary cholangitis: a 14-year longitudinal survey-based study. PLoS One 13: e0194397, 2018."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Konishi H, Fukuzawa K, Mori S, et al. Anti-mitochondrial M2 antibodies enhance the risk of supraventricular arrhythmias in patients with elevated hepatobiliary enzyme levels. Intern Med 56: 1771-1779, 2017.","DOI":"10.2169\/internalmedicine.56.8183"},{"key":"14","unstructured":"14. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 134: e579-e646, 2016."},{"key":"15","unstructured":"15. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 29: 270-276, 2008."},{"key":"16","unstructured":"16. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37: 2129-2200, 2016."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yoshihisa A, Kimishima Y, Kiko T, et al. Usefulness of urinary N-terminal fragment of titin to predict mortality in dilated cardiomyopathy. Am J Cardiol 121: 1260-1265, 2018.","DOI":"10.1016\/j.amjcard.2018.01.046"},{"key":"18","unstructured":"18. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28: 1-39.e14, 2015."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yoshihisa A, Kimishima Y, Kiko T, et al. Liver fibrosis marker, 7S domain of collagen type IV, in patients with pre-capillary pulmonary hypertension. Int J Cardiol 258: 269-274, 2018.","DOI":"10.1016\/j.ijcard.2018.01.138"},{"key":"20","unstructured":"20. Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis. chronic non-suppurative destructive cholangitis. Am J Pathol 46: 387-407, 1965."},{"key":"21","unstructured":"21. Yokokawa J, Saito H, Kanno Y, et al. Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes. J Gastroenterol Hepatol 25: 376-382, 2010."},{"key":"22","unstructured":"22. Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 60: 1046-1049, 2001."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Koyamada R, Higuchi T, Kitada A, et al. Association of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome with immune thrombocytopenia and Graves' disease. Intern Med 54: 2013-2016, 2015.","DOI":"10.2169\/internalmedicine.54.4405"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Liberal R, Gaspar R, Lopes S, Macedo G. Primary biliary cholangitis in patients with inflammatory bowel disease. Clin Res Hepatol Gastroenterol 44: e5-e9, 2020.","DOI":"10.1016\/j.clinre.2019.05.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Floreani A, Cazzagon N. PBC and related extrahepatic diseases. Best Pract Res Clin Gastroenterol 34-35: 49-54, 2018.","DOI":"10.1016\/j.bpg.2018.05.013"},{"key":"26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/gut.2009.184218","volume":"59","author":"MI Prince","year":"2010","unstructured":"26. Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 59: 508-512, 2010.","journal-title":"Gut","ISSN":"https:\/\/id.crossref.org\/issn\/0017-5749","issn-type":"print"},{"key":"27","unstructured":"27. Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L. Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47: 552-556, 2017."},{"key":"28","unstructured":"28. Katahira M, Yokokawa T, Miura S, et al. A case of non-ischemic heart failure associated with anti-mitochondrial antibody-positive myositis. SHINZO 50: 1138-1144, 2018 (in Japanese)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Matsumoto K, Tanaka H, Yamana S, et al. Successful steroid therapy for heart failure due to myocarditis associated with primary biliary cirrhosis. Can J Cardiol 28: 515.e3-515.e6, 2012.","DOI":"10.1016\/j.cjca.2011.12.010"},{"key":"30","first-page":"283","volume":"58","author":"R Klein","year":"1984","unstructured":"30. Klein R, Maisch B, Kochsiek K, Berg PA. Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases. Clin Exp Immunol 58: 283-292, 1984.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hiraoka A, Kojima N, Yamauchi Y, et al. An autopsy case of primary biliary cirrhosis with severe interstitial pneumonia. Intern Med 40: 1104-1108, 2001.","DOI":"10.2169\/internalmedicine.40.1104"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Weissman E, Becker NH. Interstitial lung disease in primary biliary cirrhosis. Am J Med Sci 285: 21-27, 1983.","DOI":"10.1097\/00000441-198305000-00004"},{"key":"33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(82)91327-7","volume":"2","author":"PA Berg","year":"1982","unstructured":"33. Berg PA, Klein R, Lindenborn-Fotinos J, Kloppel W. ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet 2: 1423-1426, 1982.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Klein R, Kloppel G, Garbe W, Fintelmann V, Berg PA. Antimitochondrial antibody profiles determined at early stages of primary biliary cirrhosis differentiate between a benign and a progressive course of the disease. A retrospective analysis of 76 patients over 6-18 years. J Hepatol 12: 21-27, 1991.","DOI":"10.1016\/0168-8278(91)90903-O"},{"key":"35","first-page":"68","volume":"74","author":"R Klein","year":"1988","unstructured":"35. Klein R, Berg PA. Characterization of a new mitochondrial antigen-antibody system (M9\/anti-M9) in patients with anti-M2 positive and anti-M2 negative primary biliary cirrhosis. Clin Exp Immunol 74: 68-74, 1988.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"36","first-page":"445","volume":"84","author":"R Klein","year":"1991","unstructured":"36. Klein R, Berg PA. Anti-M4 antibodies in primary biliary cirrhosis react with sulphite oxidase, an enzyme of the mitochondrial inter-membrane space. Clin Exp Immunol 84: 445-448, 1991.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"37","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2249.1998.00531.x","volume":"111","author":"A Otto","year":"1998","unstructured":"37. Otto A, Stahle I, Klein R, Berg PA, Pankuweit S, Brandsch R. Anti-mitochondrial antibodies in patients with dilated cardiomyopathy (anti-M7) are directed against flavoenzymes with covalently bound FAD. Clin Exp Immunol 111: 541-547, 1998.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Maisch B, Alter P. Treatment options in myocarditis and inflammatory cardiomyopathy: focus on i.v. immunoglobulins. Herz 43: 423-430, 2018.","DOI":"10.1007\/s00059-018-4719-x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/2\/60_5422-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T03:46:12Z","timestamp":1610768772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/2\/60_5422-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5422-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}